104 related articles for article (PubMed ID: 16741978)
1. Heparin-like synthetic polymers, named RGTAs, mimic biological effects of heparin in vitro.
Rouet V; Meddahi-Pellé A; Miao HQ; Vlodavsky I; Caruelle JP; Barritault D
J Biomed Mater Res A; 2006 Sep; 78(4):792-7. PubMed ID: 16741978
[TBL] [Abstract][Full Text] [Related]
2. Glycosaminoglycan mimetics (RGTA) modulate adult skeletal muscle satellite cell proliferation in vitro.
Papy-Garcia D; Barbosa I; Duchesnay A; Saadi S; Caruelle JP; Barritault D; Martelly I
J Biomed Mater Res; 2002 Oct; 62(1):46-55. PubMed ID: 12124786
[TBL] [Abstract][Full Text] [Related]
3. Structurally different RGTAs modulate collagen-type expression by cultured aortic smooth muscle cells via different pathways involving fibroblast growth factor-2 or transforming growth factor-beta1.
Alexakis C; Mestries P; Garcia S; Petit E; Barbier V; Papy-Garcia D; Sagot MA; Barritault D; Caruelle JP; Kern P
FASEB J; 2004 Jul; 18(10):1147-9. PubMed ID: 15132978
[TBL] [Abstract][Full Text] [Related]
4. Effects of heparan-like polymers associated with growth factors on osteoblast proliferation and phenotype expression.
Blanquaert F; Barritault D; Caruelle JP
J Biomed Mater Res; 1999 Jan; 44(1):63-72. PubMed ID: 10397905
[TBL] [Abstract][Full Text] [Related]
5. RGTA modulates the healing pattern of a defect in a monolayer of osteoblastic cells by acting on both proliferation and migration.
Blanquaert F; Carpentier G; Morvan F; Caruelle JP; Barritault D; Tardieu M
J Biomed Mater Res A; 2003 Mar; 64(3):525-32. PubMed ID: 12579567
[TBL] [Abstract][Full Text] [Related]
6. New concepts in tissue repair: skin as an example.
Meddahi A; Caruelle JP; Gold L; Rosso Y; Barritault D
Diabetes Metab; 1996 Jul; 22(4):274-8. PubMed ID: 8767175
[TBL] [Abstract][Full Text] [Related]
7. Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds.
Liekens S; Leali D; Neyts J; Esnouf R; Rusnati M; Dell'Era P; Maudgal PC; De Clercq E; Presta M
Mol Pharmacol; 1999 Jul; 56(1):204-13. PubMed ID: 10385702
[TBL] [Abstract][Full Text] [Related]
8. Beneficial use of fibroblast growth factor 2 and RGTA, a new family of heparan mimics, for endothelialization of PET prostheses.
Desgranges P; Caruelle JP; Carpentier G; Barritault D; Tardieu M
J Biomed Mater Res; 2001; 58(1):1-9. PubMed ID: 11152991
[TBL] [Abstract][Full Text] [Related]
9. FGFs and their receptors, in vitro and in vivo studies: new FGF receptor in the brain, FGF-1 in muscle, and the use of functional analogues of low-affinity heparin-binding growth factor receptors in tissue repair.
Soulet L; Chevet E; Lemaitre G; Blanquaert F; Meddahi A; Barritault D
Mol Reprod Dev; 1994 Sep; 39(1):49-54; discussion 54-5. PubMed ID: 7528027
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of tumor metastasis by heparanase inhibiting species of heparin.
Vlodavsky I; Mohsen M; Lider O; Svahn CM; Ekre HP; Vigoda M; Ishai-Michaeli R; Peretz T
Invasion Metastasis; 1994-1995; 14(1-6):290-302. PubMed ID: 7657522
[TBL] [Abstract][Full Text] [Related]
11. Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound.
Miao HQ; Ornitz DM; Aingorn E; Ben-Sasson SA; Vlodavsky I
J Clin Invest; 1997 Apr; 99(7):1565-75. PubMed ID: 9120000
[TBL] [Abstract][Full Text] [Related]
12. In vitro changes in plasma membrane heparan sulfate proteoglycans and in perlecan expression participate in the regulation of fibroblast growth factor 2 mitogenic activity.
Guillonneau X; Tassin J; Berrou E; Bryckaert M; Courtois Y; Mascarelli F
J Cell Physiol; 1996 Jan; 166(1):170-87. PubMed ID: 8557766
[TBL] [Abstract][Full Text] [Related]
13. Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly.
Ibrahimi OA; Zhang F; Hrstka SC; Mohammadi M; Linhardt RJ
Biochemistry; 2004 Apr; 43(16):4724-30. PubMed ID: 15096041
[TBL] [Abstract][Full Text] [Related]
14. Matrix therapy with RGTA OTR4120 improves healing time and quality in hairless rats with deep second-degree burns.
Zakine G; Barbier V; Garcia-Filipe S; Luboinski J; Papy-Garcia D; Chachques JC; Carpentier A; Barritault D
Plast Reconstr Surg; 2011 Feb; 127(2):541-550. PubMed ID: 21285759
[TBL] [Abstract][Full Text] [Related]
15. Engineering of an FGF-proteoglycan fusion protein with heparin-independent, mitogenic activity.
Yoneda A; Asada M; Oda Y; Suzuki M; Imamura T
Nat Biotechnol; 2000 Jun; 18(6):641-4. PubMed ID: 10835602
[TBL] [Abstract][Full Text] [Related]
16. Inhibition by dextran derivatives of FGF-2 plasmin-mediated degradation.
Meddahi A; Lemdjabar H; Caruelle JP; Barritault D; Hornebeck W
Biochimie; 1995; 77(9):703-6. PubMed ID: 8789459
[TBL] [Abstract][Full Text] [Related]
17. Derivatized dextrans mimic heparin as stabilizers, potentiators, and protectors of acidic or basic FGF.
Tardieu M; Gamby C; Avramoglou T; Jozefonvicz J; Barritault D
J Cell Physiol; 1992 Jan; 150(1):194-203. PubMed ID: 1370503
[TBL] [Abstract][Full Text] [Related]
18. Control of cell proliferation by heparan sulfate and heparin-binding growth factors.
Vlodavsky I; Miao HQ; Atzmon R; Levi E; Zimmermann J; Bar-Shavit R; Peretz T; Ben-Sasson SA
Thromb Haemost; 1995 Jul; 74(1):534-40. PubMed ID: 8578521
[No Abstract] [Full Text] [Related]
19. Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin.
Bitan M; Mohsen M; Levi E; Wygoda MR; Miao HQ; Lider O; Svahn CM; Ekre HP; Ishai-Michaeli R; Bar-Shavit R
Isr J Med Sci; 1995; 31(2-3):106-18. PubMed ID: 7744578
[TBL] [Abstract][Full Text] [Related]
20. Site-directed mutagenesis and molecular modeling identify a crucial amino acid in specifying the heparin affinity of FGF-1.
Patrie KM; Botelho MJ; Franklin K; Chiu IM
Biochemistry; 1999 Jul; 38(29):9264-72. PubMed ID: 10413500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
